Targeted temperature management in emergency medicine: current perspectives

Benton R Hunter, Timothy J Ellender

Department of Emergency Medicine, Department of Critical Care Medicine, Indiana University School of Medicine, Indianapolis, IN, USA

Abstract: Landmark trials in 2002 showed that therapeutic hypothermia (TH) after out-of-hospital cardiac arrest due to ventricular tachycardia or ventricular fibrillation resulted in improved likelihood of good neurologic recovery compared to standard care without TH. Since that time, TH has been frequently instituted in a wide range of cardiac arrest patients regardless of initial heart rhythm. Recent evidence has evaluated how, when, and to what degree TH should be instituted in cardiac arrest victims. We outline early evidence, as well as recent trials, regarding the use of TH or targeted temperature management in these patients. We also provide evidence-based suggestions for the institution of targeted temperature management/TH in a variety of emergency medicine settings.

Keywords: therapeutic hypothermia, cardiac arrest, heart arrest

Introduction

Cardiac arrest is common, occurring in more than 320,000 nonhospitalized people yearly in the USA alone.1 Of those treated by emergency medical services personnel, approximately 23% present with a shockable initial heart rhythm (ventricular tachycardia or ventricular fibrillation [VF]).1 Despite ongoing efforts to improve resuscitative and postresuscitative care, cardiac arrest still carries a dismal prognosis, with survival to hospital discharge occurring in 7%–11% of patients with out-of-hospital cardiac arrest (OHCA)1,2 and 25% of patients who arrest in hospital.1 Historically, once return of spontaneous circulation (ROSC) is achieved, there is little evidence to support any particular therapy or intervention. In 2002, two landmark studies3,4 reported that cooling the bodies of postarrest patients who had an initially shockable heart rhythm to 32°C–34°C for a period of time after ROSC resulted in a greater likelihood of neurologically intact survival. This therapeutic hypothermia (TH) has since become standard care for patients with ROSC after cardiac arrest. Despite a lack of high-level evidence in cardiac arrest patients with nonshockable initial rhythms or in-hospital arrest, TH is now commonly applied to any patient with ROSC after cardiac arrest, whether in hospital or OHCA, and any presenting rhythm.5,7

Recently, two large randomized trials8,9 introduced considerable controversy to the discussion about how, when, and to what degree we should be instituting temperature control in postarrest patients. The objective of this review is to give an overview of the evidence surrounding TH in patients with ROSC after cardiac arrest, and provide evidence-based suggestions for temperature management of cardiac arrest victims in a variety of emergency-medicine settings. When possible, we focus on evidence from randomized trials. We try to address specifically when, how, and to what temperature
we should be managing the temperature of postarrest patients. Lastly, we present a structure for instituting temperature control and outline some pearls and pitfalls in doing so. We use the term “targeted temperature management” (TTM) to refer to strict temperature control at any temperature. TH will be used to refer to temperature control targeting body temperatures of 32°C–34°C.

Background and pathophysiology
TTM is a form of treatment aimed at achieving and maintaining a specific core body temperature for a duration of time to improve outcomes. This is done in an attempt to reduce the risk of tissue injury from the lack of blood flow that can be seen as a result of cardiac arrest. TTM is thought to limit brain injury by decreasing cellular metabolism and the brain’s oxygen demand by reducing the production of excitatory neurotransmitters like glutamate, minimizing the disruption of ion homeostasis, and by reducing free radicals that might further injure at-risk neurons. Most centers now either actively cool or control temperature by using TH or temperature-management protocol (example in Figure 1) for 24 hours to a goal cooling temperature of 32°C–34°C.

**Return of spontaneous circulation (ROSC)**

**Airway and breathing**
- Maintain and protect airway
- Administer O₂ to maintain SpO₂ 94%–98%
- Do not hyperventilate
- Maintain respiratory rate of 10–12/minute
- Monitor ETCO₂/SpO₂; target pCO₂ 35–45 mmHg

**Circulation**
- Treat hypotension (SBP <90 mmHg)
- Consider fluid bolus
- Consider norepinephrine; begin at 0.01 µg/kg/min, titrate to an MAP goal of greater than 80 mmHg
- Obtain a 12-lead EKG
- Treat STEMI cases per protocol, consider PCI-capable facilities

**Evaluate inclusion and exclusion criteria for TTM**
- Cardiac arrest from suspected medical etiology and the patient is unresponsive (GCS <8) and hemodynamically stable

**Initiate targeted temperature management**
- Apply ice packs to axilla/chest/groin
- Administer cold IV fluids 30 mL/kg at 500 cc increments
- Monitor temperature
- Treat shivering
- Prepare for continuous cooling
- Notify inpatient unit or consider transfer to TTM-capable facilities

*Figure 1* Targeted temperature management (TTM).
*Abbreviations:* SpO₂, peripheral capillary oxygen saturation; ETCO₂, end-tidal carbon dioxide; pCO₂, partial pressure of carbon dioxide; SBP, systolic blood pressure; MAP, mean arterial pressure; EKG, electrocardiogram; STEMI, ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; GCS, Glasgow Coma Score; IV, intravenous.
or maintain normothermia at 36°C.\textsuperscript{14–16} Standard protocols aim for initiating temperature control within the 1st hours of collapse (0–6 hours) to achieve the target temperature as quickly as possible (within 8 hours of cooling initiation).\textsuperscript{14,16,17} Rewarming is typically begun 24 hours after the initiation of cooling for patients cooled to a 32°C–34°C target, and is done slowly (0.1°C–0.5°C per hour) until 36°C is reached. In some centers, temperature management is maintained at 36°C for the next 48 hours independently of initial target temperature. Likewise, centers that use 36°C as a temperature-management target typically control body temperature at this target for 72 hours.

A basic understanding of some landmark trials in TH is necessary in order to try to answer some of the questions we address in this article. TH after cardiac arrest was brought to the forefront in 2002 by two trials published in the \textit{New England Journal of Medicine}. Bernard et al\textsuperscript{1} enrolled 77 patients with ROSC after OHCA and an initial cardiac rhythm of VF in a quasi-randomized fashion. Patients assigned to TH had cold packs and ice packs applied to their head, neck, and torsos until they were 33°C. This temperature was maintained for at least 12 hours. Patients were then rewarmed with heating blankets to normothermia by 24 hours after hospital admission. Twenty-one of 43 patients (49%) assigned to hypothermia were released from the hospital with “good neurologic outcome”. This end point was achieved in only nine of 34 patients (26%) assigned to no temperature control, which was a statistically significant difference.

At the same time, a second trial was published by the Hypothermia After Cardiac Arrest (HACA) study group.\textsuperscript{4} This larger randomized trial similarly enrolled postarrest patients who had an initial rhythm that was shockable (ventricular tachycardia or VF). Of approximately 3,500 patients screened, the trial ultimately enrolled 275 patients. Those randomized to TH were cooled to a target of 32°C–34°C using cooling blankets that circulated cold air, with ice bags used additionally if necessary. This temperature was maintained for approximately 24 hours, followed by passive rewarming. This trial found that 75 of 136 patients (55%) randomized to TH had a “favorable neurologic outcome” compared to 54 of 137 (39%) of the normothermic patients. Again, this difference in outcomes was statistically significant.

The methods and duration of cooling in these trials were, as just outlined, heterogeneous, but the results were consistent and suggested a large increase in neurologically intact survival with TH employed by relatively simple methods. While these two trials have formed the backbone of support for TH after cardiac arrest, several observational studies\textsuperscript{5,7,18,19} have been published since then, mostly reporting similar benefits associated with TH. In 2002, the International Liaison Committee on Resuscitation began recommending TH be instituted in all patients with ROSC after an initially shockable rhythm and considered in those with nonshockable rhythms.\textsuperscript{20} These guidelines have not changed significantly since then.

In 2013, Nielsen et al published a much larger randomized trial that compared controlled normothermia at 36°C to controlled hypothermia at 33°C.\textsuperscript{8} This trial enrolled patients with any initial rhythm, and patients were cooled with more sophisticated equipment, which allowed more tightly controlled body temperatures. In this trial of over 950 patients, the two temperature targets were equivalent in terms of survival and neurologically intact recovery. Among the patients cooled to 33°C, mortality was 50% at the end of the trial, and 54% had either died or had poor neurologic function at 180 days. Of the patients maintained at 36°C, the corresponding numbers were 48% mortality and 52% with poor neurologic outcome or death. Results were similar for patients with shockable or nonshockable rhythms. There was no statistical difference in outcomes, and the authors concluded that TH at 33°C conferred no benefit over TTM at 36°C.

At nearly the same time, Kim et al published a negative trial of prehospital TH.\textsuperscript{9} This trial randomized 1,369 patients with OHCA to either immediate cooling by prehospital providers with cold saline (4°C) or standard prehospital management without cooling. By protocol, the patients who survived to hospital admission were to undergo TH in the hospital. Survival was 37.6% in patients cooled in the field versus 37.1% in controls. Good neurologic recovery was 32.7% in cooled patients versus 34.4% in controls. Results were similar for patients with initial shockable and nonshockable rhythms, though in-hospital TH was inconsistently applied to patients with nonshockable rhythms.

An understanding of these few trials is imperative for any informed discussion regarding the finer points of when and how to institute TTM after cardiac arrest. These trials are referenced throughout the rest of this review.

\textbf{What is the optimal temperature target?}

Prior to Nielsen et al’s study,\textsuperscript{8} data from randomized trials were limited to demonstrating that 32°C–34°C for 12–24 hours was superior to no temperature control. There was very limited evidence to guide further what exact temperature would be most beneficial. Further, this benefit was only proven in...
patients with shockable rhythms on presentation. Nielsen et al’s study showed that strict temperature management to maintain normothermia at 36°C resulted in similar outcomes to hypothermia at 33°C. The study included patients with any presenting rhythm. The authors postulated that fever avoidance was the key, as opposed to actual cooling to a hypothermic temperature. Nielsen et al did find that electrolyte abnormalities were slightly more common in patients cooled to 33°C, which is of unclear clinical meaning. In a secondary analysis, the authors also found that vasopressor requirements were higher in the hypothermic group compared to patients maintained at normothermia. It thus may be that a target of 36°C is associated with moderately fewer side effects than a hypothermic protocol, but these small differences did not result in a difference in patient-important outcomes. There are no convincing data to suggest that one temperature target is superior to another.

A recent trial representing the first randomized trial of TH versus normothermia in children found that temperature management at a goal of 36.8°C was as effective as targeting 33°C. Enrollees had their target temperature maintained for the first 48 hours, then were brought to a target of 36.8°C through a total of 120 hours of temperature control. The trial enrolled 260 patients with full outcome data, and found that survival with good neurologic recovery was 20% in the hypothermia group and 12% in the normothermia group (P=0.14). Secondary outcomes were similarly distributed and not statistically different between the groups.

Given the results of these randomized studies and lack of meaningful benefit or harm associated with hypothermia versus controlled normothermia, either temperature goal seems reasonable. Practice patterns may eventually be decided by which temperature target is easier to maintain. If a simple and inexpensive method for maintaining temperature at 36°C is validated, decreasing costs compared to hypothermia, this might make a stronger argument for normothermia. It should be pointed out, however, that both of these trials comparing TTM at different temperatures used advanced temperature-control devices in all of the enrolled patients. While these devices have not proven superior to easy, inexpensive methods (ice packs and cold saline) for patients receiving TH, their efficacy compared to simple methods has not been studied in controlled normothermia.

**Special considerations for choosing a temperature target**

Adverse events and possible complications of hypothermia may include bleeding, dysrhythmias, electrolyte abnormalities, hyperglycemia, infection, and skin breakdown. Though fatal arrhythmia produced by hypothermia is seemingly rare, sinus tachycardia is commonly seen at the time of hypothermia induction, and when body temperature falls below 35.5°C, a sinus bradycardia occurs. Typical electrocardiogram changes seen during hypothermia include an increase in the intervals between different waves (P–R, Q–T), the widening of the wave of ventricular depolarization (QRS), and occasionally a prominent J-point deflection or Osborne wave.

Serum electrolyte disturbances occur as a result of increased renal excretion of electrolytes, due to changes in circulating blood volume, cardiac preload, and impaired tubular function and as a result of intracellular shift during hypothermia. The most common electrolyte disturbances seen are magnesium deficiency and hypokalemia, though hypocalcemia, hyponatremia, and hypophosphatemia also occur with some frequency. Though many of these disturbances can be transient, preventing severe electrolyte imbalance caused by hypothermia should be the main target of electrolyte treatment.

Infection, historically the most feared risk of prolonged TH, might have no greater prevalence in this population than that of matched critically ill patients. Similarly, recent investigators found that hypothermia was associated with a small but not statistically significant trend toward increased bleeding, and found no associated increase in severe bleeding. Invasive lines, especially cooling catheters, can predispose resuscitated patients to inadvertent vascular puncture, bleeding, infection, and deep-vein thrombosis, so extreme care must be taken during placement and maintenance.

In summary, there is little evidence to suggest that meaningful complications are more common with TH than with controlled normothermia in any particular subgroup of patients. However, normothermia may be preferred in patients thought to be at particularly high risk for complications associated with hypothermia, such as severe preexisting electrolyte abnormalities, hemodynamic instability, infection, or bleeding disorders. Some of these are examples of conditions that have traditionally been considered contraindications to TH (Table 1), but may be appropriate for controlled normothermia.

**When should TTM be initiated?**

For the past decade since TH has been introduced into postarrest care, recommendations have been to start cooling patients as soon as possible after or even before ROSC. In referral centers with experience in postarrest care, the answer is relatively simple: patients should have TTM instituted as soon as they are stabilized. The question is more difficult for
Table 1 Targeted temperature management: exclusion criteria and contraindications to active cooling to a 32°C–34°C target

<table>
<thead>
<tr>
<th>Exclusion criteria</th>
<th>C target range</th>
<th>C (36.8°C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purposeful response to verbal commands or noxious stimuli after ROSC and prior to initiation of hypothermia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recurrent VF or refractory VT in spite of appropriate therapy</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Absolute contraindications**

- Hemorrhagic stroke
- Cardiac arrest due to trauma
- GCS >8
- Uncontrolled, active bleeding
- Uncontrolled hemodynamically unstable rhythms

**Relative contraindications**

- Prolonged cardiac arrest (>60 minutes)
- Refractory hypotension despite fluid and vasopressor support – consider ECMO
- Thrombocytopenia (PLTs <50K) or baseline coagulopathy

**Note:** Many of the contraindications mentioned in the table may not limit application of targeted temperature management, and institutional consensus should be followed on a case-by-case basis.

**Abbreviations:** ROSC, return of spontaneous circulation; VF, ventricular fibrillation; VT, ventricular tachycardia; GCS, Glasgow Coma Scale; ECMO, extracorporeal membrane oxygenation; PLTs, platelets.

physicians working in locations where postarrest patients will be routinely transferred to a referral center. Directors of prehospital services (emergency medical services) have also struggled with whether or not early initiation of TH in the field immediately after (or even prior to) ROSC would add benefit. Common sense would dictate that if TH or temperature control is beneficial, then earlier institution of it should improve its efficacy, and thus patient outcomes. However, evidence to support this has not been borne out.

There are conflicting results from comparative observation studies in humans undergoing TH. A small trial (n=49) in 2009 by Wolff et al found an independent association between shorter time to coldest temperature and cerebral performance-category score ≤2 (representing a favorable outcome), although there was no association with either time to TH initiation or time to target temperature. That same year, Nielsen et al reported on a much larger cohort (n=986), and found no association between time to initiation or time to target temperature and patient outcomes. In 2011, Mooney et al reported a 20% increase in mortality for every hour’s delay in TH initiation among 140 patients. The ICE study, however, found a significant independent association between early initiation of TH and increased mortality in their cohort of 121 Italian patients. Similarly, Haugk et al found improved survival (adjusted odds ratio of 1.86) among 588 patients to be independently associated with longer time to target temperature. While the results of these studies showed only associations and not causality, there is no convincing evidence that very early TH offers additive benefit over slightly delayed TH. It is also noteworthy that the median time to target temperature for patients randomized to TH in the HACA trial was relatively long, at 8 hours.

Perhaps more convincing data are now available from randomized trials regarding prehospital initiation of TH. Prior to 2013, six randomized trials of very early prehospital initiation of TH had been performed. While patients randomized to prehospital cooling generally reached target temperature faster, none of the trials found any patient-important benefit. Two meta-analyses of these trials published in 2013 and 2014 found no evidence of any clinically important benefit with prehospital TH. Then, Kim et al published their trial of 1,369 patients, nearly solidifying that prehospital TH offered no advantage over waiting to initiate TH until after hospital arrival. Kim et al’s trial did show that early rearrest and pulmonary edema were more common with prehospital cooling, suggesting that rapid infusion of cold saline for immediate cooling may be associated with significant harms, though ultimately survival and neurologic recovery were similar between groups. It should be noted that approximately 50% of the patients admitted after being resuscitated from a nonshockable rhythm in Kim et al’s trial did not actually receive in-hospital cooling, decreasing the certainty that the intervention would not have been useful had these patients undergone continued cooling after hospital arrival. Despite this uncertainty in patients with nonshockable rhythms, the bulk of the evidence is clearly in favor of no benefit with very early initiation of TH.

These results are perhaps not surprising in light of the evidence that now suggests that patients need not be actually cooled, as opposed to maintained at normothermic temperatures. Postarrest patients are generally below normothermic levels at hospital arrival. This means that as long as one believes that 36°C is an appropriate target temperature, they are already at target. Therefore, earlier initiation of “cooling” theoretically offers no benefit, as the temperature is already “controlled”, until it goes outside the range that is maintained while targeting 36°C.

Since the safety of uncontrolled temperatures above those obtained while targeting 36°C (36.8°C in children) is unproven, and perhaps doubtful, we suggest that TTM be mandatorily instituted before a patient becomes hyperthermic, but that as long as hyperthermia is avoided, the timing of initiation is otherwise likely to be of little relevance. This requires early institution of continuous temperature monitoring in all postarrest patients. Given that among those randomized to normothermia in Nielsen et al’s
study, the 95% interval around the average temperature was above 37.0°C for all time points,9 we recommend initiating aggressive temperature control measures before the (invasively measured) body temperature reaches 36.5°C. In settings where advanced techniques are not readily or quickly available, the aggressive application of ice packs to the body with or without infusion of cold intravenous fluids prior to a temperature of 36.5°C should be sufficient to avoid any significant chance of hyperthermia.

What methods should be employed to institute TTM?

The landmark trials of TH in 2002,33 as outlined earlier, used crude methods for cooling compared to today’s technologies. The main tools employed were ice packs and cold-air cooling blankets, and it took 8 hours on average to achieve TH in the HACA trial.33 It was these methods for cooling that initially appeared so effective in improving postarrest outcomes. Since that time, methods to cool patients more efficiently have been aggressively pursued. Randomized studies have sought to define ways to cool patients faster, keep temperatures closer to target, or make temperature control easier.23,41 Some methods have proven useful for these goals, but the hopes that these more efficient methods of cooling would provide improved patient outcomes have not come to fruition.

The Arctic Sun® system is a well-studied method for external cooling that uses external cooling pads placed on various parts of the patient’s body. This device mechanically circulates temperature-controlled water through dermally applied gel pads. In an often-cited study comparing Arctic Sun to cooling blankets and ice packs, patients randomized to Arctic Sun achieved target temperature more quickly (by 54 minutes on average), but good neurologic recovery was unaffected.23

Invasive means of cooling patients appear to be even more effective in terms of fast and controlled temperature control. Pittl et al41 studied the invasive CoolGuard® system against Arctic Sun in 80 postarrest patients. They found that the invasive system maintained more stable temperature control, but did not affect clinical outcomes or neuron-specific enolase levels, which the authors measured as a surrogate marker for brain damage. Bleeding complications were significantly more common in the CoolGuard group.

Pearls and pitfalls in the first 12 hours of TTM

Patients undergoing TTM after cardiac arrest are typically critically ill, and we recommend both central venous and arterial access within the early hours of care. When cooling to 32°C–34°C, early access can be critical, since the effects of peripheral vasoconstriction at a cooler goal temperature can make obtaining access markedly more difficult. The control of body temperature may be accomplished by many means, including the use of dermally applied gel and water-cooled pad devices, cooling blankets, cooling helmets, cooling catheters, ice packs, cooled fluid bolus, endovascular cooling devices, and ice-water lavage, though as outlined earlier it is unclear if any one method is superior to the others.42

Continuous core body temperature should be monitored to provide data to modulate cooling efforts and to avoid overcooling. Temperatures below 30°C (86°F) should be avoided, as adverse events, especially life threatening arrhythmia and bleeding, increase significantly below 30°C.42 Esophageal, rectal, and bladder probes have been commonly used to monitor core temperature, though data suggest that rectal temperatures can be unreliable.41 Invasive lines, such as a pulmonary artery temperature probe, can be used if available, and several endovascular and gel heat-transfer cooling systems integrate a temperature probe that is used to modulate cooling system output.

Sedation and shivering control

Patient comfort and sedation should be assessed and institutional guidelines followed regarding patient monitoring and the treatment of pain and agitation. Pain can be controlled with common narcotic analgesics, such as morphine or fentanyl, and sedation can be maintained with such agents as lorazepam, midazolam, or propofol (Table 2).

Shivering, the body’s attempt to maintain temperature homeostasis, can contribute to discomfort and interfere with a controlled thermic state, so prior to the induction of temperature management, pharmacological agents to control shivering should be administered.10,42,44–46 Shivering typically begins when a body temperature drops below a certain threshold, typically approximately 36°C, and often appears regardless of the technique used to induce hypothermia.44,45 It is unclear whether different temperature targets result in significant differences in the amount of shivering, and we believe that a similar approach and algorithm for shivering control is reasonable, regardless of the temperature target chosen.

In some cases, shivering will be controlled with routine sedative drips alone (fentanyl, propofol, benzodiazepines). When these standard measures fail, the drugs most commonly employed to prevent shivering in TTM are acetaminophen, buspirone, desflurane, dexmedetomidine, and meperidine.46–48 Common sedatives used during TH to reduce the shivering threshold include propofol, dexmedetomidine, midazolam, and diazepam. Though fentanyl and morphine are the more commonly used opiates during TTM therapy,49 meperidine
Magnesium sulfate has been studied to a level 33°C to a level 33°C. 

**Table 2** Common pharmacologic and bedside adjuncts for temperature management

<table>
<thead>
<tr>
<th>Initiation of sedation/analgesia</th>
<th>Sedation</th>
<th>Analgesia</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Initiation of shiver control</strong></td>
<td><strong>First line</strong></td>
<td>Fentanyl (Sublimaze): 0.7–10 µg/kg/h intravenous infusion</td>
</tr>
<tr>
<td>Acetaminophen (Tylenol): 650–1,000 mg orally/rectally every 4–6 hours</td>
<td>Propofol (Diprivan): 50–75 µg/kg/min intravenously to deep sedation</td>
<td></td>
</tr>
<tr>
<td>Buspirone (Buspar): 30 mg orally every 8 hours</td>
<td>Magnesium sulfate: 2–5 g infused over 5 hours</td>
<td></td>
</tr>
<tr>
<td>Meperidine (Demerol): 25–50 mg intravenously every 4 hours as needed</td>
<td>Propofol (Diprivan): 50–75 µg/kg/min intravenously to deep sedation</td>
<td></td>
</tr>
<tr>
<td>Application of arm/skin counterwarming via forced-air warming unit, hand mitts</td>
<td>Magnesium sulfate: 2–5 g infused over 5 hours</td>
<td></td>
</tr>
<tr>
<td><strong>Second line</strong></td>
<td>Dexametomidine (Precedex): 0.2–0.7 µg/kg/h intravenously for mild sedation</td>
<td></td>
</tr>
<tr>
<td>Magnesium sulfate: 2–5 g infused over 5 hours</td>
<td>Dexametomidine (Precedex): 0.2–0.7 µg/kg/h intravenously for mild sedation</td>
<td></td>
</tr>
<tr>
<td><strong>Third line</strong></td>
<td>Vecuronium (Norcuron): 0.1 mg/kg intravenous bolus as needed; can be followed by intravenous infusion 1 µg/kg/min infusion for maintenance</td>
<td></td>
</tr>
<tr>
<td>Propofol (Diprivan): 50–75 µg/kg/min intravenously to deep sedation</td>
<td>Goal: bispectral index value 40–60 or one muscle twitch out of four in train of four monitoring</td>
<td></td>
</tr>
<tr>
<td>Vecuronium (Norcuron): 0.1 mg/kg intravenous bolus as needed; can be followed by intravenous infusion 1 µg/kg/min infusion for maintenance</td>
<td>Goal: bispectral index value 40–60 or one muscle twitch out of four in train of four monitoring</td>
<td></td>
</tr>
<tr>
<td>Goal: bispectral index value 40–60 or one muscle twitch out of four in train of four monitoring</td>
<td>Rocuronium (Zemuron): 0.6–1.2 mg/kg intravenous bolus as needed, can be followed by a 0.01–0.012 mg/kg/min infusion for maintenance</td>
<td></td>
</tr>
<tr>
<td>Cisatracurium (Nimbex): 0.03 mg/kg intravenous bolus as needed; can be followed by a 1–2 µg/kg/min infusion for maintenance</td>
<td>Goal: bispectral index value 40–60 or one muscle twitch out of four in train of four monitoring</td>
<td></td>
</tr>
<tr>
<td>Goal: bispectral index value 40–60 or one muscle twitch out of four in train of four monitoring</td>
<td>Goal: bispectral index value 40–60 or one muscle twitch out of four in train of four monitoring</td>
<td></td>
</tr>
<tr>
<td>Norepinephrine (Levophed): begin at 0.01 µg/kg/min intravenously, titrate to MAP goal</td>
<td>Norepinephrine (Levophed): begin at 0.01 µg/kg/min intravenously, titrate to MAP goal</td>
<td></td>
</tr>
<tr>
<td>Epinephrine: begin at 2 µg/min intravenously (in adults), titrate to MAP goal</td>
<td>Epinephrine: begin at 2 µg/min intravenously (in adults), titrate to MAP goal</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviation:** MAP, mean arterial pressure.

has been the most efficacious of the opiates with regard to shiver management, with recorded reductions in the shivering threshold of 1.2°C–6.1°C to a level 33°C. Buspirone, a serotonin 1A partial agonist, and meperidine appear to lower the shivering threshold in synergism, achieving even lower shivering thresholds. Magnesium sulfate has been studied as a bolus with infusion as a means to improve targeted cooling times and perhaps enhance shivering thresholds in combination with other agents.

Nonpharmacologic means of shiver reduction largely focus on skin counterwarming (total-body forced-air rewarming, focal hand rewarming, and focal face/head rewarming) as a means to reduce shivering and vasoconstrictive thresholds. Evidence supports a 1°C decrease in shivering threshold for every 4°C increase in skin temperature. Endovascular cooling may allow better access to the skin to employ counterwarming compared to external cooling measures that require the skin to be cooled directly. When shivering occurs despite optimal pharmacologic and nonpharmacologic means, protocols often include the use of a paralytic agent (ie, neuromuscular blocker) to control shivering.

**Monitoring and supportive therapy**

Postarrest patients should be placed on a continuous cardiac monitor with monitoring of routine vital signs and oxygen saturation. The most commonly encountered arrhythmia associated with TH is bradycardia, and a heart rate less than 40 can be seen frequently, but is rarely a cause for concern in the absence of blood-pressure instability. In the event of life-threatening dysrhythmia, hemodynamic instability, or bleeding, active cooling should be discontinued and the patient rewarmed to a higher target. A mean arterial pressure (MAP) goal of more than 80 mmHg is preferred by some because it should theoretically support cerebral perfusion, as hypertension in the postresuscitative phase is potentially neuroprotective. Norepinephrine, beginning at 0.01 µg/kg/min, can be titrated to whatever MAP goal is thought to be best in the individual patient, though practitioners should balance MAP goals and the goal of higher cerebral perfusion with the potential complications of increasing cardiac demands.

In addition to the standard neuroprotective strategies, such as placing the head of the bed at 30°, lung-protective ventilation strategies, standard bedside line and catheter care, and pneumonia-prevention protocols should be followed. Skin condition should be checked as frequently as every 2–6 hours for potential thermal injury, which can be caused by thermal blankets or pads, and for breakdown as a consequence of vasoconstriction. Core temperature should be monitored hourly and regularly confirmed with a secondary temperature-monitoring device when actively cooling. Ventilation should be set to maintain CO₂ partial pressure within the reference range (35–45 mmHg) and
arterial blood gases followed every 6 hours, as metabolic end points change with temperature.

Patient hematologic testing, including a complete blood count, a basic metabolic panel, troponin level, arterial blood gas level, prothrombin time, and partial thromboplastin time, should be collected at temperature-management initiation (0 hour) and collected every 6–12 hours during cooling or as per institutional protocols. An elevated serum glucose level is potentially deleterious to the injured brain, and glycemic control should be maintained via institutional protocol. Hypokalemia, which may be exacerbated by insulin administration, commonly occurs as a result of intracellular shift during hypothermia. Conversely, potassium exits the cells when patients are rewarmed, and hyperkalemia may occur, especially if potassium is replaced during the rewarming phase. Potassium values less than 3.5 mEq/L should be corrected during induction and cooling, but potassium administration should be stopped at the final 2 hours of cooling and once rewarming begins.42,58

**Conclusion**

TTM remains an integral part of post-cardiac arrest care. Current evidence supports either TH at 32–34°C or controlled normothermia at 36°C, though individual patient characteristics may lead the clinician to favor one target over the other in certain cases. In a postarrest patient, continuous temperature monitoring should be initiated as soon as possible, and TTM should be started prior to any temperature greater than 36.5°C. No clinical benefit has been shown with any particular method of TTM over another, although direct normothermia-versus-hypothermia comparisons have been limited to advanced techniques. Patients undergoing TTM should have continuous cardiac monitoring and have electrolyte checks frequently, as abnormalities are common in this group of patients. Patients should be sedated, and in many cases will require further methods, as discussed, to control shivering.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


